Profitability came under strain. Gross profit fell to EUR 246m, with margins narrowing to 23.7% as negative product mix—particularly in Asia Pacific—weighed on performance
Move aligns global biologics identity under the Biocon Biologics brand
At the center of the announcement are two late-breaking studies that could reshape treatment approaches for patients with high cholesterol and a complex form of heart failure
The protections extend through at least 2035, with the potential for further extensions
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
The new shadow roll-on delivers strong on-shelf presence with its modern rounded-base design
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
The FDA is beginning rulemaking to close the “adequate provision” loophole
The board of directors accepted Hrosz’s resignation and expressed appreciation for his significant contributions during his tenure
Subscribe To Our Newsletter & Stay Updated
